Free Trial
NASDAQ:OCS

Oculis Q4 2024 Earnings Report

Oculis logo
$18.86 +1.14 (+6.40%)
As of 05/2/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Oculis EPS Results

Actual EPS
-$0.76
Consensus EPS
-$0.48
Beat/Miss
Missed by -$0.28
One Year Ago EPS
N/A

Oculis Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.21 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oculis Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Tuesday, March 11, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Oculis' Q1 2025 earnings is scheduled for Wednesday, May 14, 2025, with a conference call scheduled on Thursday, May 8, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Oculis Earnings Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Oculis Updates Share Capital
Oculis Holding (OCS) Receives a Buy from Bank of America Securities
See More Oculis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oculis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oculis and other key companies, straight to your email.

About Oculis

Oculis (NASDAQ:OCS), a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

View Oculis Profile

More Earnings Resources from MarketBeat